nd

nd - URANO

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

EU CTR

Registry ID

EUCTR2019-002451-42-IT

Enrollment

170

Registered

2021-05-24

Start date

2019-10-22

Completion date

Unknown

Last updated

2025-02-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Patients undergoing total knee replacement surgery with spinal anesthesia. MedDRA version: 20.0 Level: PT Classification code 10049548 Term: Knee operation System Organ Class: 10042613 - Surgical and medical procedures

Interventions

Product Name: Depalgos Product Code: [Depalgos] Pharmaceutical Form: Film-coated tablet INN or Proposed INN: OSSICODONE CLORIDRATO CAS Number: 76-42-6 Current Sponsor code: DEPALGOS 5 mg + 325 mg comp

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: nd Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range 85 F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range 85

Exclusion criteria

Exclusion criteria: nd

Design outcomes

Primary

Measure	Time frame
Main Objective: nd;Secondary Objective: nd;Primary end point(s): nd;Timepoint(s) of evaluation of this end point: 3 days	—

Countries

Italy

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026

nd